Dr. Sethu M. Madhavan, MD

Dr. Madhavan practices at Ohio State University Hospital in Columbus, Ohio, part of The Ohio State University Wexner Medical Center.

Dr. Madhavan's NPI, 1003015850, was assigned on July 12, 2007. Dr. Madhavan holds Ohio license 35.122245.

Dr. Madhavan's primary practice is Ohio State University Hospital, at 410 West 10th Avenue, Columbus, OH 43210 in Franklin County. The practice phone is (614) 293-9700.

Dr. Madhavan's primary practice is Ohio State University Hospital in Columbus, Ohio, part of The Ohio State University Wexner Medical Center. Dr. Madhavan is also affiliated with The James Cancer Hospital and Solove Research Institute. The medical group on file is Ohio State University Physicians. Dmand AI also links Dr. Madhavan to 2 more hospital outpatient departments, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Madhavan practices, 5 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Madhavan's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Madhavan is licensed in Ohio.

CMS data shows 279 Medicare services from Dr. Madhavan across 6 procedure codes in 2024, for 164 Medicare patients. Medicare paid $23,372 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 164 Medicare patients who saw Dr. Madhavan in 2024. The largest group is 65 to 74, with 61 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 23% are also on Medicaid. Their average risk score is 4.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Madhavan's median patient age at 64, with 42% women.

In 2024, Dr. Madhavan wrote 385 Medicare Part D claims for 62 patients. 96% of them were for generic drugs. CMS names the drug for 296 of them, across 10 drugs with 11 or more claims each, at $2,598 in total drug cost. In 2023, CMS named 222 claims across 9 drugs.

Dr. Madhavan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 26 papers to Dr. Madhavan, published from 2011 to 2025. 2017 was the busiest year, with 3. The most frequent topics are Apolipoprotein L1, Genetic Variation and Kidney. Dr. Madhavan has published most often in J Am Soc Nephrol. Dr. Madhavan's most frequent co-authors are John R. Sedor, MD, Samir V. Parikh, MD and Salem Almaani, MD.

Dmand AI links Dr. Madhavan to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Low Back Pain.

CMS Open Payments shows 3 general payments to Dr. Madhavan from 2 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 99% of the total. Vertex Pharmaceuticals Incorporated paid the most, $182.